A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

R. E. Coleman, J. M. Clarke, M. L. Slevin, J. Sweetenham, C. J. Williams, P. Blake, F. Calman, E. Wiltshaw, P. G. Harper

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (38%) evaluable patients responded, with the median duration of response being 7 months. Bone marrow and gastrointestinal toxicity were frequently severe. There were 3 septic death. Although cisplatin plus ifosfamide is an active combination against this disease, these results suggest that it is no more so than either drug used alone.

Original languageEnglish (US)
Pages (from-to)52-54
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume27
Issue number1
DOIs
StatePublished - Jan 1990
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix'. Together they form a unique fingerprint.

Cite this